Chinyere E. Okpara

1.1k total citations
26 papers, 163 citations indexed

About

Chinyere E. Okpara is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Chinyere E. Okpara has authored 26 papers receiving a total of 163 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in Chinyere E. Okpara's work include Cancer Immunotherapy and Biomarkers (16 papers), Lung Cancer Treatments and Mutations (9 papers) and Cancer Genomics and Diagnostics (6 papers). Chinyere E. Okpara is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), Lung Cancer Treatments and Mutations (9 papers) and Cancer Genomics and Diagnostics (6 papers). Chinyere E. Okpara collaborates with scholars based in United States, United Kingdom and Japan. Chinyere E. Okpara's co-authors include Corina E. Dutcus, Robert J. Motzer, Matthew H. Taylor, Vicky Makker, Toshiyuki Tamai, Gregory M. Lubiniecki, Ziad Hussein, Takuji Okusaka, T.R. Jeffry Evans and Alan D. Smith and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

Chinyere E. Okpara

20 papers receiving 160 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chinyere E. Okpara United States	7	100	100	35	34	21	26	163
Sheik Emambux France	8	77 0.8×	105 1.1×	29 0.8×	36 1.1×	32 1.5×	13	174
Krassimir Koynov Bulgaria	6	114 1.1×	195 1.9×	35 1.0×	47 1.4×	18 0.9×	12	242
Xu-Shan Sun France	7	80 0.8×	124 1.2×	22 0.6×	36 1.1×	36 1.7×	13	193
Roslyn Wallace Australia	7	98 1.0×	149 1.5×	26 0.7×	27 0.8×	21 1.0×	15	224
Matthew Labriola United States	6	159 1.6×	137 1.4×	82 2.3×	72 2.1×	28 1.3×	23	238
María Elena Elez Spain	6	59 0.6×	115 1.1×	24 0.7×	50 1.5×	9 0.4×	10	167
Antoine Angelergues France	9	130 1.3×	76 0.8×	38 1.1×	28 0.8×	17 0.8×	31	199
Lakshminarayanan Nandagopal United States	8	99 1.0×	52 0.5×	70 2.0×	57 1.7×	31 1.5×	22	183

Countries citing papers authored by Chinyere E. Okpara

Since Specialization

Citations

This map shows the geographic impact of Chinyere E. Okpara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chinyere E. Okpara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chinyere E. Okpara more than expected).

Fields of papers citing papers by Chinyere E. Okpara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chinyere E. Okpara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chinyere E. Okpara. The network helps show where Chinyere E. Okpara may publish in the future.

Co-authorship network of co-authors of Chinyere E. Okpara

This figure shows the co-authorship network connecting the top 25 collaborators of Chinyere E. Okpara. A scholar is included among the top collaborators of Chinyere E. Okpara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chinyere E. Okpara. Chinyere E. Okpara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Arance, Ana, Miguel‐Ángel Berciano‐Guerrero, Jun Guo, et al.. (2025). Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma. Annals of Oncology. 36(12). 1535–1546.

Herráez, A. Casado, Émeline Colomba, David S. Miller, et al.. (2025). 1119P Lenvatinib plus pembrolizumab (L + P) vs treatment of physician’s choice (TPC) for advanced endometrial cancer (EC): 5-year outcomes from study 309/KEYNOTE-775. Annals of Oncology. 36. S699–S700.

Eskander, Ramez N., Jung‐Yun Lee, Domenica Lorusso, et al.. (2025). TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy. Journal of the National Comprehensive Cancer Network. 23(3.5).

Herbst, Roy S., Byoung Chul Cho, Mauricio Burotto, et al.. (2025). Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study. Journal of Thoracic Oncology. 20(9). 1302–1314.

Chung, Hyun Cheol, Esma Saâda-Bouzid, Federico Longo, et al.. (2024). Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study. Cancer. 130(19). 3278–3288. 4 indexed citations

Motzer, Robert J., Camillo Porta, Masatoshi Eto, et al.. (2024). Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.. Journal of Clinical Oncology. 42(16_suppl). 4504–4504. 7 indexed citations

Motzer, Robert J., Camillo Porta, Masatoshi Eto, et al.. (2024). Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma. Annals of Oncology. 36(4). 375–386. 6 indexed citations

González-Martı́n, Antonio, Hyun Cheol Chung, Esma Saâda-Bouzid, et al.. (2024). Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study. Gynecologic Oncology. 186. 182–190. 8 indexed citations

Evans, T.R. Jeffry, Masatoshi Kudo, Ann‐Lii Cheng, et al.. (2024). ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy.. Journal of Clinical Oncology. 42(16_suppl). 4094–4094. 1 indexed citations

10.

Colombo, Nicoletta, Domenica Lorusso, Bradley J. Monk, et al.. (2023). Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab. The Oncologist. 29(1). 25–35. 4 indexed citations

11.

Herbst, Roy S., Byoung Chul Cho, Caicun Zhou, et al.. (2023). 64O Lenvatinib plus pembrolizumab, pemetrexed, and a platinum (len + pembro + chemo) as first-line therapy for metastatic non squamous non-small cell lung cancer (NSCLC): Phase III LEAP-006 study. Immuno-Oncology Technology. 20. 100536–100536. 3 indexed citations

12.

Leighl, Natasha B., Luis Paz‐Ares, Delvys Rodríguez‐Abreu, et al.. (2023). 65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy. Immuno-Oncology Technology. 20. 100537–100537. 8 indexed citations

13.

Gruenwald, Viktor, Rana R. McKay, Tomáš Büchler, et al.. (2023). 1903P Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial. Annals of Oncology. 34. S1024–S1025. 2 indexed citations

14.

Motzer, Robert J., Camillo Porta, Masatoshi Eto, et al.. (2023). Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology. 41(16_suppl). 4502–4502. 25 indexed citations

15.

Okpara, Chinyere E., et al.. (2022). Comparative results of focal-cryoablation and stereotactic body radiotherapy in the treatment of unilateral, low-to-intermediate-risk prostate cancer. International Urology and Nephrology. 54(10). 2529–2535. 3 indexed citations

16.

Yang, James Chih‐Hsin, Alexander Luft, Emmanuel de la Mora Jimenez, et al.. (2021). 120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study. Annals of Oncology. 32. S1429–S1430. 18 indexed citations

17.

Gaspar, Nathalie, Quentin Campbell‐Hewson, Stefan Bielack, et al.. (2020). 443TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082). Annals of Oncology. 31. S1414–S1415.

18.

Gaspar, Nathalie, Quentin Campbell‐Hewson, Stefan Bielack, et al.. (2020). 1668TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082). Annals of Oncology. 31. S990–S991. 2 indexed citations

19.

Siu, Lillian L., Barbara Burtness, Kevin J. Harrington, et al.. (2020). 973TiP LEAP-010: Phase III study of first-line pembrolizumab with or without lenvatinib in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Annals of Oncology. 31. S683–S684. 1 indexed citations

20.

Cruz, Filemon S. Dela, Elizabeth Fox, Jodi A. Muscal, et al.. (2020). A phase I/II study of lenvatinib (LEN) plus everolimus (EVE) in recurrent and refractory pediatric solid tumors, including CNS tumors.. Journal of Clinical Oncology. 38(15_suppl). 10527–10527. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sheik Emambux Breakdown of academic impact, for papers by Krassimir Koynov Breakdown of academic impact, for papers by Xu-Shan Sun Breakdown of academic impact, for papers by Roslyn Wallace Breakdown of academic impact, for papers by Matthew Labriola Breakdown of academic impact, for papers by María Elena Elez Breakdown of academic impact, for papers by Antoine Angelergues Breakdown of academic impact, for papers by Lakshminarayanan Nandagopal